After hosting investor meetings with management, William Blair analyst Jon Andersen says shares of Prestige Brands have been "unduly punished." Despite a "draconian pullback" in the stock, fiscal 2018 has been a "reasonable year" for Prestige, Andersen tells investors in a research note. The analyst expects to see "relative share price outperformance" over the next couple of years. His thesis remains that Prestige's core brand portfolio targeting the over-the-counter healthcare market and free cash flow productivity supports earnings growth in the upper single digits. He keeps an Outperform rating on the shares.